Risks and benefits of postmenopausal combined hormone replacement therapy

Tattersall, Martin H N

doi:10.5694/j.1326-5377.2002.tb04724.x

Topics

In 1997, South Australian women around the age of menopause had one of the highest reported rates of hormone replacement therapy (HRT) use in the world.1 Among women aged 55–64 years, 60% had used HRT and nearly 40% were current users, with a mean length of HRT use of 70 months.

1 *Professor Tattersall is writing on behalf of the ADEC Expert Committee (L F Arnolda, B K Armstrong, R A Ayton, J J McNeil, M Michael, D J Topliss).
2 Department of Cancer Medicine, University of Sydney, NSW.

Correspondence: mtatt@med.usyd.edu.au

1. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy in women at risk of cardiovascular disease and osteoporosis in South Australia in 1997. Med J Aust 1999; 170: 524-527.
2. MacLennan AH. Long-term hormone replacement therapy. Aust Prescriber 2000; 23: 90-92.
3. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 1268-1269.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333.
5. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366-368.

Online responses are no longer available. Please refer to our instructions for authors page for more information.